Phreesia Stock Price, News & Analysis

Phreesia, Inc. (NYSE: PHR) reported fiscal first quarter 2023 results, revealing a 31% revenue growth to $63.4 million compared to $48.3 million last year. The average number of healthcare services clients rose by 33% to 2,526, though average revenue per client fell by 5% to $19,193. Adjusted EBITDA was negative $30.6 million, down from positive $0.1 million in the previous year. The company maintains a fiscal 2023 revenue outlook of $271 million to $275 million, projecting a 27% to 29% growth. Adjusted EBITDA guidance improved, now estimated at negative $126 million to negative $122 million.

KLAS and Phreesia announce a report on patient preferences regarding healthcare technology based on a survey of nearly 13,000 patients. The findings reveal patients' desire for digital tools like online appointment scheduling and telehealth services. Key insights indicate that younger patients value digital access, yet many experience gaps in what is offered by providers. Furthermore, the report emphasizes the importance of patient engagement and the need for healthcare organizations to adapt their services to meet these preferences.

Phreesia has been recognized by Becker’s Healthcare as one of the 150 Top Places to Work in Healthcare for 2022. This accolade highlights the company’s commitment to diversity, employee engagement, and professional growth. CEO Chaim Indig expressed pride in the recognition, emphasizing the company's supportive culture and opportunities for development. Phreesia's internal engagement platform, “Life@Phreesia,” focuses on wellness and community involvement, underlining the company's dedication to fostering a positive work environment.

Phreesia has been recognized as one of the 2022 Best Places to Work in Healthcare by Modern Healthcare for the sixth time. CEO Chaim Indig expressed pride in this accolade, highlighting the dedication of its remote workforce to improving healthcare experiences. This recognition reflects employee feedback, encompassing evaluations on culture, leadership, and benefits. The award honors organizations that prioritize support for their staff amidst challenges in the healthcare sector.

Phreesia announces Danielle Lynch's recognition as one of the 2022 PM360 ELITE 100 for her influential role in healthcare marketing. Honored in the Sales MVPs category, Lynch has significantly contributed to the company's growth since its IPO in 2019, helping to double the size of the Client Experience team and achieve a remarkable 77% revenue expansion during fiscal year 2022. Her innovative team-building approach fosters a collaborative culture, enhancing client partnerships and driving success.

Phreesia (NYSE: PHR) announced it will release its fiscal Q1 2023 financial results on June 2, 2022, after market close. A press release and a quarterly stakeholder letter will accompany the results and be available on its investor website. Following the release, the company will hold a conference call at 5:00 PM ET to discuss these results. Phreesia provides healthcare organizations with a SaaS platform for patient intake management, aimed at improving patient engagement and clinical efficiency.

Phreesia has announced that Danielle Lynch, Vice President of Client Experience, is recognized among the 'Women to Watch' by MM+M. This accolade honors influential leaders in healthcare marketing, with Lynch being one of only 25 selected for 2022.

Since Phreesia's IPO in 2019, Lynch has doubled her team and contributed to a nearly 100% increase in Life Sciences revenue, showcasing her innovation and leadership. David Linetsky praised her for building the Client Experience team that drives Phreesia Life Sciences' growth.

Phreesia, Inc. (NYSE: PHR) reported financial results for Q4 and FY 2022, emphasizing a strong revenue growth of 39% year-over-year to $58.0 million in Q4, and 43% growth to $213.2 million for the fiscal year. Despite increased revenues, Adjusted EBITDA was negative $30.5 million for Q4 and negative $59.0 million for the full year. Cash reserves stood at $313.8 million. Looking ahead, the company forecasts FY 2023 revenue between $271 million and $275 million, indicating a growth of 27% to 29%, but expects Adjusted EBITDA to worsen before recovering in FY 2025.

Phreesia, Inc. (NYSE: PHR) will host a conference call on March 30, 2022, at 5:00 p.m. ET to discuss its fiscal fourth quarter 2022 financial results. A press release detailing these results will be issued before the call, following market close on the same day. The company provides a suite of applications to enhance patient intake processes through its innovative SaaS platform, improving patient engagement and clinical care efficiency.